Samit Hirawat was appointed Director of Pacira BioSciences, Inc. As of November 14, 2026, Pacira BioSciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 28, 2026, naming 2 appointments (Form 8-K, January 28, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Pacira BioSciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Pacira BioSciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-28. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Pacira BioSciences, Inc. files it.
Also on the record for Pacira BioSciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G/A, by Vanguard Capital Management | 4.82% of the class | 5%+ stakes | Source |
| October 13, 2026 | Stake report, Schedule 13D/A, by Doma Perpetual Capital Management LLC | — | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.2% of the class | 5%+ stakes | Source |
| May 1, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.15% of the class | 5%+ stakes | Source |
| May 1, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 6.38% of the class | 5%+ stakes | Source |
| April 9, 2026 | Stake report, Schedule 13G, by Dimensional Fund Advisors LP | 5.1% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 12, 2026 | Stake report, Schedule 13D/A, by DOMA PERPETUAL CAPITAL MANAGEMENT LLC | 7.3% of the class | 5%+ stakes | Source |
| January 2, 2026 | Stake report, Schedule 13D/A, by Doma Perpetual Capital Management LLC | 6.83% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Renaissance Technologies LLC | 4.98% of the class | 5%+ stakes | Source |
| November 10, 2025 | Stake report, Schedule 13D/A, by Doma Perpetual Capital Management LLC | 6.83% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G, by Renaissance Technologies LLC | 5.34% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Pacira BioSciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Pacira BioSciences, Inc. and the records around it.
Pacira BioSciences, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Renaissance Technologies LLC also filed stake reports on 48 other companies: Bolt Biotherapeutics, Inc. (Nov 2026), CORE MOLDING TECHNOLOGIES INC (Nov 2026), Hello Group Inc. (Nov 2026)
- Dimensional Fund Advisors LP also filed stake reports on 366 other companies: Acadia Healthcare Co Inc (Oct 2026), ADT Inc (Oct 2026), AGCO Corp (Oct 2026)
- STATE STREET CORPORATION also filed stake reports on 378 other companies: 4D MOLECULAR THERAPEUTICS INC (Nov 2026), ACADIA PHARMACEUTICALS INC (Nov 2026), ALBEMARLE CORP (Nov 2026)
Watch Pacira BioSciences, Inc.
Get an email when Pacira BioSciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pacira BioSciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Pacira BioSciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pacira BioSciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-01-28 | In | Director | 8-K, 2026-01-28 | ||
| 2026-01-28 | In | 8-K, 2026-01-28 |
Who leads Pacira BioSciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Samit Hirawat, appointed (filed 2026-01-28).
New leaders reset buying decisions — get the Full Report on Pacira BioSciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Pacira BioSciences, Inc., with the record behind each one.
Find candidates like Director at Pacira BioSciences, Inc.Every change, in the filing's words
Appointed: Samit Hirawat, Director
On January 27, 2026, the Board of Directors (the "Board") of Pacira BioSciences, Inc. (the "Company"), pursuant to the Amended and Restated Certificate of Incorporation of the Company and the Third Amended and Restated Bylaws of the Company, approved an increase of the size of the Board from nine directors to 10 directors, and appointed Dr. Samit Hirawat to the Board, to serve as a Class III director, effective immediately.
Appointed: Samit Hirawat
The Board also concurrently appointed Dr. Hirawat to the Science and Technology Committee of the Board.
- As compensation for service on the Board, Dr. Hirawat will receive the Company's standard compensation for non-employee directors.
Tools for this story
Each opens in a new tab, filled in for Pacira BioSciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
